RoastMyFolio Logo
RoastMyFolio
Market Commentary$PLTR

Palantir: The Cult of the 160x Multiple

PLTR trades at 159x earnings while insiders dumped $167M. With an Army security scandal brewing, is this AI darling priced for god?

By Nurse Mercy4 min read

Come into my office, darling, and hop up on the table; you're looking a little feverish over PLTR again. You think you've found the holy grail of AI, but I suspect you're just intoxicated by Alex Karp's hair and a graph that goes up and to the right—let's see if your portfolio can actually survive the crash.

Nurse Mercy with whiteboard: Priced for God. Built by Mortals.

The Diagnosis

Verdict: Momentum Trap / Extreme Risk

PLTR is a Momentum Trap. While the business is executing at an elite level with 70% growth, the stock is priced for "God Mode" perfection at 159x earnings. The "Smart Money" is selling while you buy, and a classified Army scandal threatens to shatter the "Zero Trust" narrative. Proceed with extreme caution.

The Vitals

PLTR Key Metrics Summary
MetricValueSignal
Revenue$1.41B (+70% YoY)Explosive
US Commercial Growth+137% YoYHyper-Growth
Valuation~159x Forward P/EExtreme
Insider Selling$167M sold (90 days)Bearish

The Pathology

1. Valuation Vertigo (The "God Mode" Premium)

The Fact: PLTR is trading at nearly 70x Sales and 159x Forward Earnings. To justify this price, the company basically needs to execute flawlessly for a decade without a single bad quarter.

You aren't investing; you're gambling on perfection. If growth slows even slightly to 50%, the multiple collapses, and your equity evaporates. You are buying a Lamborghini for the price of a rocket ship.

2. The "Black Swan" Infection (The Army Scandal)

The Fact: A leaked US Army memo regarding the NGC2 battle system flagged "critical deficiencies" in security, leading to shareholder fraud investigations in late 2025.

Palantir's brand is built on being "unhackable." If the military starts doubting their security, the $10 billion government pipeline is at risk. This is a festering wound the market is ignoring.

3. The Insider Exodus (Follow the Smart Money)

The Fact: While retail investors are piling in, executives like the CTO and CFO dumped over $167 million in stock in the last three months.

If they believed the stock was going to $300 next year, they'd be holding. They are distributing paper to you at the top. When the chefs won't eat their own cooking, you should probably put down the fork.

The Steel-Man (Bull Case)

Now, I know why you're obsessed with her. If PLTR truly becomes the "Microsoft of AI," this valuation might actually be cheap in ten years.

The "Agentic" Monopoly: They aren't just selling chatbots; they are selling "Agents" that actually do things (like re-routing supply chains autonomously).

The Commercial Explosion: US Commercial revenue growing at 137% is unheard of at this scale. The "Bootcamps" are converting customers faster than anyone else.

If they maintain triple-digit commercial growth and the Army scandal blows over, the stock could push toward $250. But that is a "Scenario A" gamble, not an investment.

Nurse's Orders

1. Watch the $125 Support Level

This is the "line in the sand." If it breaks below $125, the technical structure breaks, and we could see a flush down to $100. Set your alerts accordingly.

2. Monitor the "Canaries" (Insider Activity)

Stop listening to the earnings calls and start watching the SEC filings. If Alex Karp or Shyam Sankar stop selling and start buying, then you know the bottom is in. Until then, assume they are cashing out.

3. Track the Army News Cycle

Set alerts for "NGC2" and "Army Contract." Any confirmation of paused contracts due to security flaws is your signal that the "Black Swan" is landing. This is your early warning system.

Bottom Line

PLTR is priced for god but built by mortals. The fundamentals are elite, but the valuation demands perfection. Wait for either the $125 support test or insider buying before adding to positions.

Tags

#pltr#momentum-trap#high-risk#ai-stocks

How Sick Is Your Portfolio?

Get a free diagnosis.

Analyze My Portfolio